Riskpilot← Back to searchSign inGet full accessExocure Sweden AB
ABActiveOrg 5594276569Erik Dahlbergsgatan 11 AManufacture of pharmaceutical preparations · NACE 2120Est. 20232 employees
Revenue 2024
SEK 2,6M
EBITDA margin
-33.4%
-128% vs 2023
Equity ratio
81.2%
Financial strength
Net profit 2024
SEK -845K
-122% vs 2023
| Revenue | SEK 2,6M | — |
| EBITDA | SEK -870K | -128% |
| Net profit | SEK -845K | -122% |
| Total assets | SEK 4,9M | -31% |
| Equity | SEK 3,9M | -18% |
| Employees | 2 | — |
Legal name
Exocure Sweden AB
Org number
5594276569
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
24 mars 2023
Share capital
SEK 26 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Lötvall, Jan Olof Persson, Mats Göte Uno Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Utveckling och försäljning av diagnostiska och terapeutiska hjälpmedel inom medicin och veterinärmedicin, utveckling av kits och andra hjälpmedel inom biomedicin, affärsutveckling inom området, och därmed förenlig verksamhet. Huvudsaklig inriktning ska vara mot extracellulära vesiklar och exosomer.
Address
Erik Dahlbergsgatan 11 A
Email
magnus.kall@ventures.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 2 606 |
| Staff expenses | — | — |
| EBITDA | −382 | −870 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −382 | −870 |
| Net financials | 3 | 25 |
| Profit before tax | −380 | −845 |
| Tax | −0 | −0 |
| Net profit | −380 | −845 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 7 043 | 4 866 |
| Equity | 4 794 | 3 949 |
| Long-term debt | 0 | 0 |
| Short-term debt | 2 249 | 917 |
| Total debt | 2 249 | 917 |
EBITDA margin
-33.4%
This company
15.8%
Market median
-311% vs market
20232024
Equity ratio
81.2%
This company
38.2%
Market median
+113% vs market
20232024
Return on equity
-21.4%
This company
18.4%
Market median
-216% vs market
20232024
Net profit margin
-32.4%
This company
8.1%
Market median
-500% vs market
20232024
Asset turnover
0.54×
This company
1.12×
Market median
-52% vs market
20232024
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JR Audit | Audit | 2023 |
SM Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Deputy Board Member | 2023 | |
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (1) | ||
| Board of Directors | 2023 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 67% | 67% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Jan Lötvall Holding AB
Exocure Sweden AB Board members of Exocure Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Robert Brunell | Audit | 0 companies |
| Søren Melsing Frederiksen | Chief Executive Officer | 0 companies |
| Klementina Österberg | Deputy Board Member | 0 companies |
| I A Catharina Gustafsson Wallich | Board of Directors | 0 companies |
| Jan Olof Lötvall | Board of Directors | 0 companies |
| Richard Arne Bergström | Board of Directors | 0 companies |
| Michael Kane | Board of Directors | 0 companies |
| Anette Helena Lundquist | Board of Directors | 0 companies |
| Mats Göte Uno Persson | Chairman | 0 companies |